2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit

Exciting results are expected this year, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73, CD39 and A2AR!

To ensure the community can capitalize on this, the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit will be returning this June (20 – 22) in Boston, MA – dedicated to bringing together 80+ industry experts to tackle the biggest problems the field continues to face in discovering translating and clinically developing CD73, CD39, A2A and A2B focused therapeutics.

Join this unmissable 3-day meeting to explore the biology of the receptors and enzymes opening doors to new therapeutic opportunities at the discovery stage, utilize novel technologies and approaches through translation to clinical development to improve patient selection, and discover new ways of finding mono and combo therapy approaches to increase potency and safety.

Download the event guide to see the presentations and speaker faculty.